E
ELTX icon

Ergoteles’s Elicio Therapeutics ELTX Stock Holding History

Ergoteles’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,291
Closed -$42.9K – 1394
2022
Q4 		$42.9K Sell
5,291
-2,595
-33% -$23.6K ﹤0.01% 1309
2022
Q3 		$73K Sell
7,886
-1,047
-12% -$10.9K ﹤0.01% 1410
2022
Q2 		$102K Buy
+8,933
New +$143K ﹤0.01% 1502
2021
Q3 		– Sell
-2,392
Closed -$311K – 1334
2021
Q2 		$311K Buy
+2,392
New +$345K 0.01% 1051

Other funds holding ELTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ergoteles's ELTX Position: Q1 2023 in Review

Ergoteles sold out of Elicio Therapeutics (ELTX) in Q1 2023, closing a stake of 5,291 shares — an estimated $42.9K sold.

Ergoteles first reported a position in ELTX in Q2 2021 and held it in 4 quarters. The position peaked at $311K in Q2 2021. 28 funds tracked by Wall St. Rank hold ELTX as of Q1 2023.

  • Ergoteles reported no remaining Elicio Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 5,291 Elicio Therapeutics shares in Q1 2023, an estimated $42.9K.
  • Ergoteles first reported a position in Elicio Therapeutics in Q2 2021 and held it in 4 quarters.
  • Ergoteles's Elicio Therapeutics position peaked at $311K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.